Latest News-I-Mab Mediaroom_Page

I-Mab Announces Upcoming Participation at November Conferences

SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2021-11-03 20:00 1180

I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments

SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2021-11-01 20:00 1287

I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China

* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process,...

2021-10-26 20:00 1662

I-Mab Expands U.S. Footprint with New R&D Site in San Diego

- I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, ...

2021-10-22 20:00 1520

I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-10-18 20:00 1393

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China

* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with...

2021-10-13 20:00 1141

I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage...

2021-10-05 20:00 9070

I-Mab Announces Upcoming Participation at October Conferences

SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2021-10-01 20:00 14236

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab

* The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted ...

2021-09-30 20:00 6054

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-09-28 20:00 3630

I-Mab Added to FTSE ESG Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-09-13 20:00 4411

I-Mab Added to FTSE Russell Global Equity Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-09-02 20:00 5584

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021

* 13 significant clinical milestones achieved year-to-date, including critical positive data read...

2021-08-31 18:00 3227

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-08-30 20:00 1519

I-Mab Announces Establishment of Environmental, Social and Governance Committee

* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * ...

2021-08-19 19:00 3412

I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021

SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-08-17 20:00 2356

Latest News